A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372 | Completed Phase 1

• 1 other identifier: 114112
• Study Type: interventional
• Target: 52
• Locations: 1 country
• Sites: 1

Brief Summary

This will be a randomized, double-blind, placebo- controlled cross-over study to investigate the effect of GEn on cardiac repolarisation parameters compared with placebo and a positive control, moxifloxacin. Approximately 52 subjects will be recruited to the study and will take part in four dosing sessions. Subjects will receive, in a randomized order, a single dose of 1200 mg GEn, 6000 mg GEn (supratherapeutic dose), 400 mg moxifloxacin (positive control) and placebo. Twelve lead continuous ECG monitoring will be conducted from pre-dose to approximately 24 hours after dosing on Day 1 of each study session. The primary comparison of interest will be the mean change from baseline in the time-matched differences in QTcF between each GEn treatment and placebo.

Conditions

Restless Legs Syndrome

Keywords

GEn, moxifloxacin, cardiac repolarisation, QT/QTc

Outcome Measures

Primary Outcomes (1)

• Change in QTcF (QT duration corrected for heart rate by Fridericia's formula) interval at Each time point for 6000 mg GEn and Placebo measured by ECG

  Day -1-Day2

Secondary Outcomes (7)

• Change in QTcF interval at Each time point for 1200 mg GEn and Placebo measured by ECG

  Day -1-Day 2

• Change from baseline in QTcF interval at each time point for moxifloxacin 400 mg and placebo measured by ECG

  Day -1-Day 2

• Change from baseline in QTcB (QT duration corrected for heart rate by Bazett's formula), QT for GEn (1200 mg and 6000 mg) and moxifloxacin (400 mg) and placebo measured by ECG

  Day -1-Day 2

• Change from baseline in PR, QRS intervals, heart rate and ECG waveform morphology for GEn (1200 mg and 6000 mg) and placebo measured by ECG

  Day -1-Day 2

• Change from baseline in heart rate and ECG waveform morphology for moxifloxacin (400 mg)

  Day -1-Day 2

Study Arms (4)

Treatment 1

EXPERIMENTAL

Healthy Volunteers will receive Treatments ABDC

Drug: GEn 1200mg; Drug: Moxifloxacin Placebo

Treatment 2

EXPERIMENTAL

Healthy Volunteers will receive Treatments BCAD

Drug: Gen 6000 mg; Drug: Moxifloxacin Placebo

Treatment 3

EXPERIMENTAL

Healthy Volunteers will receive Treatments CDBA

Drug: GEn Placebo

Treatment 4

EXPERIMENTAL

Healthy Volunteers will receive Treatments DACB

Drug: GEn Placebo; Drug: Moxifloxacin

Interventions

GEn 1200mg DRUG

1200 mg of Gen administered as a single dose

Also known as: gen1200

Treatment 1

Gen 6000 mg DRUG

6000 mg of Gen administered as a single dose

Also known as: gen6000

Treatment 2

GEn Placebo DRUG

Placebo to match GEn Tablets

Treatment 3; Treatment 4

Moxifloxacin Placebo DRUG

Placebo to match Moxifloxacin

Treatment 1; Treatment 2

Moxifloxacin DRUG

400 mg Moxifloxacin administered as a single dose

Also known as: moxifloxacin 400

Treatment 4

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECG. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
• Male or female between 18 and 50 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and estradiol less than 40 pg/ml (less than 147 pmol/L) is confirmatory\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method; Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit is completed.
• Body weight greater than and equal to 50 kg and BMI within the range 19 - 30 kg/m2 (inclusive)
• Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
• Creatinine clearance (CrCl) greater than and equal to 80 mL/min. CrCl is estimated using the equation of Cockcroft and Gault. See study procedure manual for details on creatinine clearance calculations.
• AST, ALT, alkaline phosphatase and bilirubin less than and equal to 1.5xULN (isolated bilirubin greater than and equal to 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).

You may not qualify if:

• The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
• A positive test for HIV antibody.
• Has cardiac conduction abnormalities on the screening 12-lead ECG denoted by any of the following: QTcB or QTcF interval greater than 450 msec; PR interval greater than 200 msec or less than and equal to 110 msec; Evidence of second- or third- degree atrioventricular block (AVB); Pathological Q-waves (defined as Q-wave greater than 40 msec or depth greater than 0.4- 0.5mV); Evidence of ventricular pre-excitation; Electrocardiographic evidence of complete left bundle branch block (LBBB), right bundle branch block (RBBB), incomplete LBBB; Intraventricular conduction delay with QRS duration greater than 120 msec
• The subject has a screening heart rate less than 50 or greater than 100 bpm or a systolic blood pressure greater than 140 or less than 100 mmHg or a diastolic blood pressure greater than 90 or ;ess than 60 mmHg in the semisupine position
• Subjects with a personal or family history of QTc prolongation, symptomatic cardiac arrhythmias or cardiac arrest
• Serum calcium, magnesium or potassium levels outside the reference range
• History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of greater than 14 drinks/week for men or greater than 7 drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled spirits.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
• Exposure to more than four new chemical entities within 12 months prior to the first dosing day
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. Hormone replacement therapy and contraceptive medication will be allowed in this study.
• History of sensitivity to quinolone antibiotics, gabapentin, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Lactating females or pregnant females as determined by positive serum hCG test at screening or prior to dosing.
• Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.

Sponsors & Collaborators

• XenoPort, Inc.: lead

Study Sites (1)

GSK Investigational Site

Austin, Texas, 78744, United States

Location

Related Publications (1)

• Davy M, Upward J, Arumugham T, Twomey C, Chen C, Stier B. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther. 2013 Dec;35(12):1964-74. doi: 10.1016/j.clinthera.2013.10.011. Epub 2013 Nov 28.

  PMID: 24290737 DERIVED

MeSH Terms

Conditions

Restless Legs Syndrome

Interventions

Holliday Junction Resolvases; Moxifloxacin

Condition Hierarchy (Ancestors)

Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Parasomnias; Mental Disorders

Intervention Hierarchy (Ancestors)

Endodeoxyribonucleases; Deoxyribonucleases; Esterases; Hydrolases; Enzymes; Enzymes and Coenzymes; Endonucleases; Recombinases; Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 19, 2012
• First Posted: January 24, 2012
• Study Start: January 1, 2012
• Primary Completion: March 1, 2012
• Study Completion: March 1, 2012
• Last Updated: April 12, 2021

Record last verified: 2021-04

Locations

US (1)